check_circleStudy Completed

Postmenopause, Pharmacokinetics

Bayer Identifier:

91222

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available
Study to assess drospirenone's (DRSP) potential to inhibit Cytochrome P450 3A4 in healthy postmenopausal women

Trial purpose

Please see attached Study Results Summary below.

Key Participants Requirements

Sex

N/A

Age

N/A

Trial summary

Enrollment Goal
25
Trial Dates
May 2003 - September 2003
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Drospirenone (DRSP, BAY86-5131)
Accepts Healthy Volunteer
N/A

Primary Outcome

Secondary Outcome

Trial design

Double-blind, randomized, crossover study to assess drospirenone's (DRSP) potential to inhibit Cytochrome P450 3A4 by evaluating the interaction between DRSP at steady state and single doses of the model substrate midazolam in healthy postmenopausal women
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to marketed products.